The present invention is concerned with diazaspiroalkanone substituted oxazole derivatives that selectively modulate regulate and/or inhibit signal transduction mediated by certain native and/or mutant protein kinases implicated in a variety of human and animal diseases such as cell proliferative metabolic autoimmune allergic and degenerative disorders. In particular the presently disclosed compounds are Syk inhibitors.